Mankind Pharma, Alkem, and Glenmark Launch Low-Cost Diabetes Drug; Prices Drop 90%

With the expiration of Boehringer Ingelheim’s patent for Empagliflozin on March 1, several domestic pharmaceutical companies have launched affordable versions of the popular diabetes medication in India.

Leading the charge are Mankind Pharma, Alkem Laboratories, and Glenmark Pharmaceuticals, offering their generic versions at significantly reduced prices.

Price Reduction Brings Affordable Treatment to Millions

Mankind Pharma has introduced its version of Empagliflozin at ₹5.50 per tablet, marking a 90% price reduction from Boehringer Ingelheim’s innovator drug Jardiance, which was priced at ₹59 per tablet, as per news reports.

This is one of the most significant price drops in diabetes treatment history, expected to enhance accessibility for millions of patients in India.

Alkem Laboratories has also entered the market, launching Empanorm, which is priced approximately 80% lower than the innovator drug.

Glenmark Pharmaceuticals has launched its Empagliflozin-based products under the Glempa brand.

Why This Price Drop Matters for India’s Diabetes Crisis

India has the second-largest diabetic population in the world, after China, making affordable diabetes medication a critical healthcare necessity. The domestic market for Empagliflozin is estimated at ₹800 crore, and with 50% projected volume growth, these price reductions are expected to drive widespread adoption of the drug.

Competition Among Indian Pharma Companies Benefits Patients

The entry of multiple domestic pharma companies into the Empagliflozin market is fostering competition, leading to:

• Lower treatment costs for diabetes patients.
• Greater availability of affordable medications across India.
• Innovation in packaging and security features, ensuring authenticity and safety.
• Expansion into Tier-2 and Tier-3 cities, increasing access for underserved populations.

Share Price Performance

Mankind Pharma share price traded at ₹2,284.10, down 1.92% at 10:05 AM on the NSE. Alkem Laboratories share price was slightly up 0.31%, trading at ₹4,614.65. Meanwhile, Glenmark Pharmaceuticals gained 1.60%, reaching ₹1,334.25.

Conclusion

The introduction of affordable Empagliflozin by Mankind Pharma, Alkem, and Glenmark marks a major milestone in diabetes care in India. With prices dropping by up to 90%, millions of patients can now access high-quality treatment at a fraction of the cost.

The competitive landscape created by domestic pharmaceutical giants ensures that life-saving medication is not just effective but also economically viable for the masses.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.